Stage IV Inflammatory Breast Carcinoma
3 clinical trials · Condition
◉ Watch Stage IV Inflammatory Breast Carcinoma
| Record | Firm | Date |
|---|---|---|
| Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer (NCT02892734) | Northwestern University | 2017-09-18 |
| Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery (NCT02658812) | M.D. Anderson Cancer Center | 2016-08-01 |
| Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy (NCT02411656) | M.D. Anderson Cancer Center | 2015-06-11 |
Track Stage IV Inflammatory Breast Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.